Anti-52 kDa Ro, anti-60 kDa Ro, and anti-La antibody profiles in neonatal lupus

Patrick Gordon, Munther A. Khamashta, Eric Rosenthal, John M. Simpson, Gurleen Sharland, Antonio Brucato, Franco Franceschini, Katrien De Bosschere, Lydie Meheus, Pier Luigi Meroni, Graham R V Hughes, Jill Buyon

Research output: Contribution to journalArticlepeer-review


Objective. Studies suggest that anti-52 kDa Ro antibodies are more sensitive and specific than anti-60 kDa Ro antibodies for neonatal lupus. However, these studies mainly used immunoblot or ELISA using recombinant protein, which have poor sensitivity for anti-60 kDa Ro antibodies. In addition, the control patients were not disease matched. We reassessed the sensitivity and specificity of anti-52 kDa Ro, anti-60 kDa Ro, and anti-La, addressing these limitations. Methods and Results. To assess sensitivity, 125 mothers of children with neonatal lupus (NLM) were recruited. All maternal sera were assessed using a commercial line immunoassay that uses natural 60 kDa Ro protein (Inno-Lia™ ANA Update, Innogenetics NV, Gent, Belgium). By this method, 96% of the sera had antibodies to 60 kDa Ro, 86% to 52 kDa Ro, and 78% to 48 kDa La. Immunoblot of 65 NLM showed significantly fewer positive results for anti-60 kDa Ro (p <0.001) and anti-52 kDa Ro (p <0.05). Sensitivity of the 3 antibodies was assessed in the symptomatic mothers of children with congenital heart block (CHB) (78 women) and disease matched controls with unaffected children (65 women) using Inno-Lia™ ANA Update. The sensitivity of each antibody was compared by multiple logistic regression to adjust for maternal disease. There was no significant difference between the groups for 60 kDa Ro or for anti-52 kDa Ro antibody. However, there was a significant difference for the anti-La antibody (p = 0.001), with an odds ratio of 3.59. This translates to an increase in risk from a published 2% for CHB in an anti-Ro-positive mother to 3.1 % if the woman is also anti-La antibody-positive, and to a decrease in risk to 0.9% if anti-La-negative. Conclusion. Contrary to previous reports, 52 kDa Ro as detected by Inno-Lia™ ANA Update is not more specific for or frequent in CHB than 60 kDa Ro. However, the presence of anti-La antibodies significantly increases the risk for CHB.

Original languageEnglish
Pages (from-to)2480-2487
Number of pages8
JournalJournal of Rheumatology
Issue number12
Publication statusPublished - Dec 2004


  • Congenital heart block
  • Neonatal lupus rash

ASJC Scopus subject areas

  • Rheumatology
  • Immunology


Dive into the research topics of 'Anti-52 kDa Ro, anti-60 kDa Ro, and anti-La antibody profiles in neonatal lupus'. Together they form a unique fingerprint.

Cite this